NIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 Independent Clinical Trial Not Allowed)
- Response deadline
- May 26, 2027 Due in 282 days
- Date posted
- Sep 2, 2025
- Source
- Open notice
Description
This Notice of Funding Opportunity (NOFO) invites R25 applications to support the development and implementation of summer research education programs for high school students, undergraduates, or science teachers from all backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences. It is essential to expand and broaden the skilled Alzheimer's Disease (AD) and Alzheimers Disease Related Dementias (ADRD) research workforce and provide exposure to AD/ADRD research to individuals early in their careers. The proposed research education programs will support intensive summer research experiences in the AD/ADRD field with the goal of exposing participants to AD/ADRD research and encourage further study or participation in biomedical and behavioral research. This NOFO does not allow participants to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.
Classifications
- NAICS93.866
Documents (1)
- DownloadRFA-AG-26-011-Full-Announcement.htmltext/html429 B
Contacts
- grantsinfo@nih.gov301-402-2541
Similar contracts
- Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)Due Oct 25, 2027
- Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)Due Mar 5, 2027
- NIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program (R25 Independent Clinical Trial Not Allowed)Due May 26, 2027
- Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)Due Jan 10, 2028
- Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)Due Sep 7, 2028
- Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)Due May 7, 2028